Not currently recruiting at UC Irvine
Safety and Efficacy of Lacutamab in Patients With Relapse Peripheral T-cell Lymphoma That Express KIR3DL2
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Innate Pharma
- ID
- NCT05321147
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 40 study participants
- Last Updated